Midwest Center for Metabolic and Cardiovascular Research
The goal of this clinical trial is to compare the relative bioavailability of coenzyme Q10 (CoQ10) from acute administrations of a CoQ10 product designed for enhanced absorption versus a standard CoQ10 product in healthy men and women. Participants will be asked to come to the clinical on five different occasions, including a screening visit (visit 1, -7 days), two test 1 visits (visits 2 and 3, days 0 and 1), and two test 2 visits (visits 4 and 5, days 7 and 8). During the start of each test visit (visits 2 and 4), the participant will consume each study product with water and a standardized breakfast meal. Then, blood samples will be collected over a 10-hour period, and a standardized lunch, dinner, and snacks will be provided. The participant will return to the clinic the next morning for a blood draw 24 hours after the study product ingestion from the previous day. The same procedures will be repeated 7 to 14 days later with the other study product.
The study products will include 100 mg CoQ10 product designed for high absorption (administered as two 50 mg capsules) and 100 mg standard CoQ10 product (administered as two 50 mg capsules).
Inclusion Criteria: 1. Male or female, between 21 and 65 y of age. 2. Individual has a BMI of 18.5 to 34.9 kg/m2. 3. Individual has a score ≥7 on the Vein Access Scale. 4. Individual is willing to discontinue any dietary supplement use for two weeks prior to visit 2 and throughout the end of the testing period. 5. Individual is judged by the Investigator to be in generally good health on the basis of medical history and screening/baseline measurements. 6. Individual understands the study procedures, including maintaining usual physical activity pattern and refraining from vigorous physical ac…
100 mg CoQ10 product designed for high absorption (administered as two 50 mg capsules)
100 mg standard CoQ10 product (administered as two 50 mg capsules)
Arctuva estimate
Verify or correct the compensation shown for this listing.